Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Dr Charles C. Hong is a physician-scientist with background in molecular biology, developmental biology, chemical biology, and cardiovascular genetics. He is an Associate Professor of Cardiovascular Medicine, Pharmacology, and Cell and Developmental Biology, and a member of the Veterans Affairs Tennessee Valley Healthcare System.? He is also a member of the Vanderbilt Institute of Chemical Biology and the Vanderbilt Center for Stem Cell Biology.?Dr. Hong received his MD-PhD with Honors from Yale, then completed cardiology fellowship at Massachusetts General Hospital, where he was a Schreyer Fellow, and postdoctoral fellowship at Harvard Medical School, where he was a Sarnoff Scholar. After a brief stint on the Harvard Medical School faculty, Dr. Hong came to Vanderbilt in 2006.?The Hong laboratory is focused on Chemical Biology of vertebrate development and stem cell differentiation, specifically Chemical Genetics of Embryonic Development; Regenerative Chemical Biology & Drug Discovery/ Experimental Therapeutics.
Dr Ada S. Ao, Postdoctoral Research Fellow, Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University, USA.
Prof Jijun Hao, Research Assistant Professor, Western University of Health Sciences, USA.
Preface xiii
1 Wnt Signaling in Regulation of Stem Cells 1David T. Paik and Antonis K. Hatzopoulos
1.1 Overview of Wnt Signaling 1
1.2 Wnt Signaling in Embryonic Stem Cells 2
1.3 Wnt Signaling in Cardiovascular Progenitor Cells and Cardiomyocyte Differentiation 3
1.4 Wnt Signaling in Mesenchymal Stem Cells 5
1.5 Wnt Signaling in Hematopoiesis and Hematopoietic Stem Cells 7
1.6 Wnt Signaling in Neural Stem Cells 8
1.7 Wnt Signaling in Endothelial-Mesenchymal Transition 8
1.8 Conclusion 9
References 10
2 Directed Cardiomyogenesis of Pluripotent Stem Cells 15Jeffery B. Bylund and Antonis K. Hatzopoulos
2.1 Introduction 15
2.2 A Brief Review of Heart Development 16
2.2.1 Cellular and Morphological Movements 16
2.2.2 Molecular Events in Heart Development 19
2.2.2.1 Molecular Events of Mesoderm Derivation 19
2.2.2.2 Transcription Factors in Cardiac Development 20
2.2.2.3 Major Developmental Signaling Pathways in Cardiac Development 22
2.3 Introduction to Pluripotent Stem Cells 23
2.3.1 Unique Features of Pluripotent Stem Cells 23
2.3.2 Pluripotent Stem Cell Sources 24
2.3.3 Maintaining Pluripotency 24
2.4 Cardiomyocyte Differentiation 25
2.4.1 Inducing Differentiation 25
2.4.2 Directed Cardiomyogenesis 26
2.5 Conclusion 28
References 29
3 Chemical Genetics in Cardiomyocyte Generation 35Daqing Jin, Qiao Li, and Tao P. Zhong
3.1 Introduction 35
3.2 iPSC Generation 36
3.3 The Chemical Genetics Approach in iPSC Generation 37
3.4 Heart Regeneration 40
3.5 The Chemical Genetics Approach in Heart Regeneration 42
3.6 Cardiac Cell Transdifferentiation 43
3.7 Conclusion 44
Acknowledgements 44
References 44
4 Challenges and New Directions for Cardiac Reprogramming 49Young-Jae Nam and Nikhil Munshi
4.1 Introduction 49
4.2 Strategies for Heart Repair 49
4.3 Direct Reprogramming Approaches 50
4.4 Current Challenges 53
4.5 Conclusion 56
Acknowledgements 56
References 56
5 Comparative Analysis of Adult Stem Cell Niches 59Bryan A. Fioret and Antonis K. Hatzopoulos
5.1 Adult Stem Cells 59
5.2 Adult Stem Cell Niches 60
5.3 The Hair Follicle Stem Cell (HFSC) Niche 61
5.4 The Intestinal Stem Cell (ISC) Niche 63
5.5 The Hematopoietic Stem Cell (HSC) Niche 66
5.5.1 Endosteal Niche 66
5.5.2 Vascular Niche 67
5.5.3 Progeny "Niche" 68
5.6 The Neural Stem Cell (NSC) Niche 68
5.6.1 V-SVZ Niche 69
5.6.2 SGZ Niche 70
5.7 A Comparison between Tissue-Specific Adult Stem Cell Niches 71
5.8 Future Challenges 73
Acknowledgements 73
References 73
6 Chemicals and Stem Cells in the Promotion of Regeneration 77Dikshya Bastakoty, Sarika Saraswati, and Pampee P. Young
6.1 Introduction 77
6.2 Biologics in Regenerative Medicine 78
6.2.1 Growth Factors and Pro-Angiogenic Agents 78
6.2.2 Immune-Modulatory Therapies 79
6.2.3 Extracellular Matrix-Based Approaches 79
6.3 Chemicals and Biomaterials for Healing 79
6.3.1 Small Molecules 80
6.3.2 Biomaterial Scaffold and Sustained Delivery 81
6.4 Stem-Cell Therapy 81
6.4.1 Chemical Manipulation of Stem Cells in Regeneration 82
6.4.2 Embryonic Stem Cells (ESCs) 82
6.4.2.1 Small Molecules for the Culture and Maintenance of ESCs 82
6.4.2.2 Small Molecules for ESC Differentiation 83
6.4.3 Induced Pluripotent Stem Cells (iPSCs) 84
6.4.3.1 Generation of iPSCs 84
6.4.3.2 Small Molecules that Affect iPSC Epigenomes 84
6.4.3.3 Small Molecules that Affect iPSC Signaling Pathways 84
6.4.4 Mesenchymal Stem Cells (MSCs) 85
6.4.4.1 Properties of MSCs 85
6.4.4.2 Small Molecules that affect MSC Differentiation 85
6.4.4.3 Biopolymers that affect MSC Biology 86
6.4.5 Hematopoietic Stem Cells (HSCs) 86
6.5 Conclusion 87
References 88
7 Chemically Induced Pluripotent Stem Cells (CiPSCs): A Potential Chemical Biological Breakthrough in Reprogramming? 95Calvin C. Sheng, Jijun Hao, and Charles C. Hong
7.1 Searching for the "Perfect" Platform 95
7.2 Defining the Advantages of Small Molecules in Reprogramming 96
7.3 Understanding the Disadvantages of Using Small Molecules 97
7.4 Breakthrough: The CiPSC Paradigm 97
7.5 Conclusion 101
References 101
8 An Introduction to Cellular Reprogramming: The Plasticity of Cell Fates and Identities 103Kelly P. Smith, Maria Borowski, and Joseph C. Laning
8.1 Defining Cell Potency 104
8.2 Types of Pluripotent Cell 105
8.2.1 Isolated Cell Types 105
8.2.1.1 Embryonal Carcinoma Cells 105
8.2.1.2 Embryonic Stem Cells 105
8.2.1.3 Embryonic Germ Cells 105
8.2.2 Reprogrammed Cell Types 106
8.2.2.1 Cell-Fusion Hybrids 106
8.2.2.2 Somatic Cell Nuclear Transfer Cells 106
8.2.2.3 Induced Pluripotent Stem Cells 106
8.3 Defining Pluripotency 107
8.4 The Molecular Basis of Pluripotency 108
8.5 Cellular Reprogramming: Altering the Epigenetic State 110
8.6 Cellular Reprogramming: Primary Regulatory Pathways 111
8.6.1 Temporal and Stoichiometric Considerations 113
8.6.2 Target Cell Type 113
8.7 Reprogramming Methods 114
8.7.1 Viral-Driven 114
8.7.2 Nucleic Acid/Episomal-Driven 115
8.7.3 mRNA-Driven 117
8.7.4 miRNA-Driven 117
8.7.5 Protein-Driven 118
8.7.6 External Factors/Enhancers 118
8.7.7 Direct Reprogramming 120
8.8 Applications and Future Trends 121
8.8.1 Moving Toward Clinical Applications for Cellular Reprogramming 121
8.8.2 The Merging of Stem Cells and New Methods of Genetic Engineering 125
8.8.3 Efficiency, Expense, and Safety 125
8.8.4 Developing Standards 126
8.9 Conclusion 127
References 127
9 Chemicals Facilitating Reprogramming 141Zhong-Dong Shi, Federico Gonz¿alez, and Danwei Huangfu
9.1 Introduction 141
9.2 Chemicals Modulating Epigenetic Barriers 145
9.2.1 Histone Deacetylase Inhibitors 146
9.2.2 Histone Methyltransferase Inhibitor and Demethylase Inhibitor 147
9.2.3 DNA Methyltransferase Inhibitors 149
9.3 Chemicals Targeting Signaling Pathways 150
9.3.1 TGFß Signaling Inhibitors 150
9.3.2 Wnt Signaling and GSK3 Inhibitors 151
9.3.3 Other Kinase Inhibitors and Activators 152
9.3.4 Cell Senescence Alleviators 153
9.4 Chemicals Promoting Lineage Reprogramming 154
9.5 Conclusion 155
References 156
10 Chemicals Facilitating Reprogramming: Targeting the SAM Binding Site to Identify Novel Methyltransferase Inhibitors 163Jeong-Do Kim, Jong S. Rim, Robert B. Crochet, Yong-Hwan Lee, Jaroslaw Staszkiewicz, Ru Gao, and Kenneth J. Eilertsen
10.1 Introduction 163
10.2 DNA Methyltransferases, Inhibition, and Reprogramming 164
10.3 DNMT Inhibitors 164
10.4 Histone Methyltransferases, Inhibition, and Reprogramming 167
10.5 Inhibitors of Lysine Methyltransferases 168
10.6 Identification of DNMT1 Inhibitor Candidates Using Virtual Screening 169
10.6.1 Functional Screening Using a DNMT1 Activity Assay 169
10.7 Targeting the SAM Binding Site to Identify Novel HMT Inhibitors 171
10.7.1 SAM Competitive Assay 173
10.7.2 SAM Binding Site is Unique and Selective across Multiple Epigenetic Targets 173
10.8 Conclusion 177
References 177
11 Biomaterials for Directed Differentiation 181Xintong Wang, Angela L. Zachman, Simon Maltais, and Hak-Joon Sung
11.1 Introduction 182
11.2 Natural Biomaterials 183
11.2.1 ECM-Derived Materials 183
11.2.1.1 Matrigel 183
11.2.1.2 Fibrin 184
11.2.1.3 Collagen 185
11.2.1.4 Laminin 187
11.2.2 Non-ECM-Derived Materials 188
11.2.2.1 Chitosan 188
11.3 Synthetic Biomaterials 189
11.3.1 Polyesters 189
11.3.1.1 Poly(Lactic Acid) and Poly(Glycolic Acid) Copolymers 189
11.3.1.2 Poly(e-Caprolactone) 192
11.3.2 Polyethylene Glycol 194
11.4 Conclusion 195
References 196
12 Practicalities to Translation from the Clinic to the Market 203Devyn M. Smith
12.1 Introduction 203
12.2 Commercialization Comparison with Small Molecules, Medical Devices, and Biologics 204
12.3 Historical Review and Case Studies 205
12.3.1 Dermagraft 205
12.3.2 Provenge 206
12.4 Commercialization Challenges and How to Overcome Them 209
12.5 Translation from the Bench to the Clinic: Key Considerations 209
12.6 Conclusion 213
References 214
Index 217
David T. Paik and Antonis K. Hatzopoulos
Department of Medicine, Vanderbilt University, USA
The Wnt signaling pathway is classically divided into so-called canonical and noncanonical branches based on the activation of specific intracellular components. Canonical Wnt signaling is activated when Wnt ligands bind to the Frizzled (Fzd) family of 7-transmembrane domain receptors and co-receptors, such as low-density lipoprotein receptor-related protein (LRP) 5/6, Ryk, and Ror2 [1–4]. This disrupts the formation of the β-catenin destruction complex, which consists of the scaffolding protein Axin, the Adenomatous polyposis coli (APC) protein, Dishevelled (Dsh), casein kinase Iα (CK-Iα), and glycogen synthase kinase-3Inase (CK). The dissociation of the destruction complex leads to stabilization of cytoplasmic iationein, which translocates to the nucleus to interact with TCF/LEF transcription factors and initiate transcription of canonical Wnt signaling target genes, such as c-Myc, Axin2, and Snail [5–7]. When canonical Wnt signaling is turned off, the destruction complex phosphorylates β-catenin for ubiquitin-mediated proteosomal degradation [8].
Noncanonical Wnt signaling pathways are β-catenin-independent and are mediated through other intracellular proteins [1–4, 9,10]. In the Wnt/JNK pathway, binding of Wnt to Fzd receptors activates small-GTPases, RhoA, and Rac through recruitment of Dsh, which thereby activate Rho kinase and c-Jun N-terminal kinases (JNK). In the Wnt/Ca+2 pathway, binding of Wnt to Fzd receptors increases intracellular Ca2+ levels, activating calcium/calmodulin-dependent kinase (CaMK) II, protein kinase C (PKC), and the protein phosphatase calcineurin (CaCN) to trigger dephosphorylation of NF-AT transcription factors. Thus activated NF-AT transcription factors translocate to the nucleus to stimulate transcription of their target genes [11]. Intriguingly, noncanonical Wnt signaling has been shown to inhibit canonical Wnt signaling in various mechanisms [10, 12, 13].
To date, 19 Wnt ligands and 10 Fzd receptors have been identified. The 19 Wnt genes fall into 12 conserved Wnt subfamilies, which exist in most mammalian genomes, including the human genome [14]. Different combinations of individual Wnt ligands, receptors, and co-receptors allow differential activation of β-catenin-dependent/canonical Wnt signaling, βWnt signaling, ligands, receptors, and/or Wnt signaling in a cellular context-dependent manner.
In the past 2 decades, the connection between Wnt signaling and human disease has been well established. Numerous components of the pathway have been implicated in cancer, obesity, osteoporosis, diabetes, and cardiovascular diseases [15]. Interestingly, Wnt signaling components are also critical regulators of stem and progenitor cells in various organs and tissues. A thorough understanding of the Wnt signaling pathway in the regulation of stem cells will be instrumental in translating the potential of stem cells to effective therapeutic solutions for human degenerative diseases or to the restoration of organ function after injury.
Wnt signaling has been implicated in the maintenance of the pluripotency and differentiation potential of embryonic stem cells (ESCs). A number of studies have demonstrated that individual Wnt ligands can stimulate self-renewal of ESCs [16–18]. Activation of the canonical Wnt pathway complements the LIF/JAK-STAT pathway via upregulation of the Stat3 gene to inhibit ESC differentiation [16]. Paracrine and autocrine Wnt signaling is essential not only for self-renewal of mESCs but also to inhibit differentiation into epiblast stem cells (epiSCs) [7]. Accordingly, mutations in the βn of the io destruction complex APC protein increase β-catenin levels, diminishing the differentiation capacity of mouse ESCs (mESCs) into the three germ layers [19].
In contrast, whether Wnt signaling promotes self-renewal or differentiation of human ESCs (hESCs) has been rather controversial. In the presence of supportive feeder cells or a conditioned medium (CM) rich in factors preventing differentiation, Wnt3a enhanced self-renewing proliferation of undifferentiated hESC H1 cells. In the absence of CM, however, activation of Wnt signaling accelerated both proliferation and differentiation of hESCs [20]. The canonical Wnt ligand Wnt1 displayed the same effects on hESCs as Wnt3a, while the noncanonical Wnt ligand Wnt5a did not affect the proliferation of hESCs, indicating that β-catenin-dependent canonical Wnt activation is responsible for enhanced hESC proliferation [21,22]. Activation of the canonical Wnt pathway by 6-bromoindirubin-3′-oxime (BIO), a specific inhibitor of glycogen synthase kinase 3 (GSK3), produced comparable results in maintaining the undifferentiated phenotype of hESCs marked by sustained expression of the pluripotent transcription factors OCT3/4 (POU5F1), REX1, and NANOG and by prevention of the epithelial–mesenchymal transition (EMT) of hESCs [23,24]. In complementary fashion, addition of the Wnt inhibitors Sfrp-1, Sfrp-2, and Sfrp-4, singly or in combination, promoted differentiation of hESCs [22].
However, other studies have reported that canonical Wnt activation disrupted hESC self-renewal and promoted differentiation. Specifically, conditional activation of stabilized β-catenin in KhES-1 and KhES-3 lines resulted in downregulation of the pluripotent markers NANOG, SOX2, and POU5F1 and upregulation of the mesodermal marker T Brachyury, followed by induction of the ventral mesodermal and endothelial marker KDR (VEGFR2) and the early cardiac marker NKX2.5 [25].
Experimental evidence also suggests that canonical Wnt signaling interacts with Activin/Nodal and bone morphogenetic protein (BMP) signaling pathways to specify differentiation lineages in hESCs. Canonical Wnt activation induced Activin/Nodal and BMP signaling to promote posterior Primitive Streak (PS) and mesoderm differentiation of hESCs. Synergistic interaction between Wnt and Activin/Nodal pathways was shown to be required for anterior PS and endoderm specification, while BMP and MAPK signaling antagonized it [25]. Recent studies have also shown that hESCs treated with the Wnt inhibitor IWP are maintained as pluripotent, with the ability to differentiate into neural cells [26]. Furthermore, Wnt3a-treated hESCs acquired PS-like characteristics and differentiated into mesodermal and endodermal cells [26].
It is noteworthy that the effects of Wnt3a on hESCs and mESCs differ significantly. In mESCs, Wnt3a prevented progression of mESCs to EpiSCs, while in hESCs Wnt3a facilitated their differentiation into mesodermal and endodermal lineages [7, 26]. In another study, the pluripotent marker OCT4 in hESCs was shown to repress β-catenin during self-renewal, whereas knockdown of OCT4 activated canonical Wnt signaling [27]. In support of these studies, Wnt1-treated hESCs displayed induced differentiation to hemogenic endothelial cells, while treatment with the Wnt inhibitor Dkk1 reduced this differentiation potential [28].
The apparently contradictory reports of Wnt signaling in hESC self-renewal and differentiation may be due to the epiblast origin of the various hESC lines tested [25]. It has also been proposed that the effects of Wnt signaling on hESCs are highly sensitive to the level of Wnt activation [26,27]. Therefore, it is likely that apparently contradictory results regarding the role of Wnt signaling in human ESC pluripotency, proliferation, and differentiation reflect the heterogeneity of the corresponding lines and their sensitivity to canonical Wnt signaling levels.
Wnt signaling also plays important roles in the maintenance and expansion of cardiovascular progenitor cells and in their differentiation into endothelial and cardiomyocyte lineages [2, 10, 11]. The mammalian heart is one of the first organs to form during embryogenesis and Wnt signaling has been implicated in all phases of cardiogenesis. Initially, canonical Wnt signaling is necessary for the formation of mesodermal progenitor cells, but it must then be suppressed in order for mesoderm progenitors to yield cardiac progenitor cells (CPCs) [11]. Subsequently, noncanonical Wnt signaling is necessary for the specification of CPCs. Wnt5a, a noncanonical Wnt activator, is upregulated by the mesoderm-specific transcription factor Mesp-1 to promote formation of CPCs [29]. Other studies have shown that intrinsic Wnt2 expression in mouse ES cells is essential for efficient cardiomyocyte differentiation and that exogenous Wnt2 promotes cardiomyocyte differentiation. Interestingly, Wnt2 induced cardiogenesis through activation of the noncanonical JNK/AP-1 pathway [30]. After CPC specification, canonical Wnt signaling activation stimulates proliferation of Isl1+ CPCs, whereas subsequent Dkk1 inhibition of canonical Wnt signaling and noncanonical Wnt activation by Wnt11 are required for cardiomyocyte differentiation [31,32].
The role of Wnt signaling and the effects of Wnt signaling manipulation during heart development have been well documented in various animal models. In mouse embryos, deletion of β-catenin in the definitive endoderm led to formation of multiple hearts along the anterior–posterior (A/P) axis, as one of the earliest pieces of evidence to implicate Wnt signaling in the endoderm in the...
Dateiformat: ePUBKopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet – also für „fließenden” Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.